Biomerica (BMRA)
(Delayed Data from NSDQ)
$0.63 USD
+0.03 (5.72%)
Updated May 1, 2024 04:00 PM ET
After-Market: $0.65 +0.02 (3.16%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Biomerica, Inc. [BMRA]
Reports for Purchase
Showing records 21 - 40 ( 44 total )
Company: Biomerica, Inc.
Industry: Medical - Drugs
Reports 2Q16 Results; Maintaining BUY Rating and $2.85 PT
Provider: Merriman Curhan Ford & Co.
Analyst: D SILVA A
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Reports 4Q15 Results; Maintaining BUY Rating and $2.85 PT
Provider: Merriman Curhan Ford & Co.
Analyst: D SILVA A
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Uneventful 3Q15 Results But The Company Establishes Advisory Board For New IBS Product
Provider: Merriman Curhan Ford & Co.
Analyst: D SILVA A
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Reports 1Q15 Results; Maintaining BUY Rating and $2.85 PT
Provider: Merriman Curhan Ford & Co.
Analyst: D SILVA A
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Reports 3Q14 Results; Maintaining BUY Rating and $2.85 PT
Provider: Merriman Curhan Ford & Co.
Analyst: D SILVA A
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Detecting Strong Upside Potential; Initiating Coverage With a BUY Rating and $2.85 PT
Provider: Merriman Curhan Ford & Co.
Analyst: D SILVA A